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Summary.-Sixteen chronic myeloid leukaemia (CML) patients in remission were
tested with solubilized membrane antigens from CML leukaemic cells, CML blasts,
AML blasts and ALL blasts for cellular immunity in vitro by lymphocyte transforma-
tion (LT) and leucocyte migration inhibition (LMI) assays. Twelve CML patients in
remission were tested with allogeneic PHA-transformed normal lymphoblasts. As
controls, peripheral-blood leucocytes from 9 healthy persons were tested with the
same antigen preparations. It was seen that 8/16 (50%) CML patients responded to
CML antigens by both LT and LMI assays, while 5/16 (31o0) patients reacted to CML
blasts and 440o (7/16) patients reacted to AML blast antigens. It was interesting to
note that 5/11 (45°/,) CML patients reacted to ALL blast antigens by both assays. One
out of 12 patients reacted to PHA-transformed lymphoblasts. None of the healthy
controls reacted to leukaemia-associated antigens. The results suggest the sharing of
antigens between myeloid leukaemic cells, myeloid blasts and lymphoid blasts.
CELLULAR senisitization to leukaemia-
associated antigens in patients suffering
from acute leukaemias has been well
documented (Freedman & Kourilsky,
1969; Levanthal et al., 1972; Santos et al.,
1973; Anderson et al., 1974). The degree
of cellular immunity has been correlated
with the clinical stage of the disease
(Giutterman et al., 1973; Char et al., 1973).
In our earlier studies we reported that
chronic myeloid leukaemia (CML) patients
in remission show cell-mediated immunity
to solubilized autochthonous and allo-
geneic leukaemic cell-membrane antigens
when tested by the leucocyte migration
inhibition (LMI) assay (Gangal et al.,
1976). We have also attempted to follow
up a small group of patients through 2-3
cycles of remissions and relapses and tried
to correlate the leukaemia-associat,ed reac-
tivity with the prognosis of the disease
(Grangal et al., 1977).
One of the major features of CML is
that at the terminal stage of blastic crisis,
the disease clinically resembles acute
myeloid leukaemia (AML) (WVintrobe,
1974). Sometimes at this stage the clinical
and haematological picture is such that it
is difficult to distinguish myeloblasts from
lymphoblasts (Wintrobe, 1974; Boggs,
1974). In the present series ofexperiments,
we have tried to investigate the reactivity
ofCML patients in remission to solubilized
CML antigens and antigens extracted from
CML blasts, AML blasts, ALL blasts and
PHA-aetivated normal allogeneic lympho-
blasts, using lymphocyte transformation
and leueocyte migration inhibition assays.
MATERIALS AND METHODS
A?dtiqens.- Leukaemic cells were collected
from the peripheral blood of 6 CML patients
with high WBC count (150,000 to 200,000)
1 AML patient having 89% blasts and 2 ALL
patients having 63% blasts. These patients
had not received anytherapy when theirblood
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was collected for antigen preparations. Anti-
gen wNas also extracted from one CML patient
showing blastic crisis. He had 810% blast cells
in the peripheral blood at the time of antigen
preparation. Peripheral-blood lymplhocytes
of one healthy individual wrere stimnulated
in vitro with PHA. At the end of incubation
for 72 h, the cultured cell population con-
tained more than 60% morphologically iden-
tifiable blasts. Solubilized antigens wrere
extracted from the membranes of leukaeemic
as well as PHA-transformned blasts using 3m
KC1 extractioni procedures as described by
Meltzer et al. (1971). The protein contents of
the antigen preparations were adjusted to
1 mg/ml with phosphate-buffered saline after
sterilization by millipore filtration (045 )um).
The antigens were stored in small aliquots at
-25°C.
Leucocyte/lynphocyte samples for testigtrl.-
Leucocytes/lymphocytes obtained from CML
patients in remission and from healthy con-
trols w-ere tested for leucocyte migration
inhibition (LMI) and lymphocyte transforma-
tion (LT) with the antigens mentioned above.
CML patients in "remission" were clinically
asymptomatic, wNith no physical signs of
illness. Liver and spleen wsere not palpable.
WVBC counts wN-ere in the range of 10,000 to
15,000/mm3 wi-ith absence or occasional
presence of premature cells. Marrow- showied
normal cellularity, normal myeloid matura-
tion and normal megakaryocytes. The cells
were collected from patients betw-een 2
months and 2 years of remission. They Nwere
either on maintenance therapy with myleran
(2 mg twice a meek) or wi-ere devoid of any
therapy. Most of them wN-ere in the first cycle
ofremission. A few wrere in the second or third
cycle of remnission.
Leucocyte inigrationi inhibition (L1MI) assay.
The procedure for LMI assay w-as essentially
as described earlier (Gangal et al.. 1976). The
indices of the migration of leucocytes in the
presence ofantigens were calculated consider-
ing migration in controls as 100%. Migration
indices (MI) ranging from 0 8 to 1P2 were
considered as within the normal range. Tests
with MI <0-8 were categorized as "'inhibi-
tion" and those wN,ith MI > 1P2 as "enhance-
ment", denoting weak sensitization (Cochran
et al., 1974).
Lymiphocyte transform)ation (LT) assay.-
Lymphocytes wAere separated from heparin-
ized peripheral blood on Ficoll-Hypaque
gradient (density 1-068-1-07) as described by
Boyum (1968). Separated lymphocytes wrere
washed x 3 with saline and suspended in
RPMI 1640+10% foetal calf serumn (FCS,
Difeo) at the cell concentration 106/Ml.
0 2 mll ofthe lymphocyte suspension was then
incubated in microtubes (4 x 0(5 cmn) alone,
with PHA (W1'ellcome, 10 1ul of 1:10 dilution
per tube) as a positive control and writh 50 yg
of the respective antigens, at 37°C in humnidi-
fied 500 CO2 atmosphere. 005 FLCi of [3H]-
thymidine (sp. act. 6000-9000 mCi/miim,
BARC, Bombay) was added to every culture
16 h before harvesting. Lvnmphocyte trans-
formnation obtained in cultures treated wN,ith
PHA, harvested after 72 h. served to confirm
the suitability of culture conditions. Cultures
receiving antigens wvere harvested after 6days.
All the tests wN-ere done in duplicate. The cell
content from each tube wA-as transferred to
No. 3 W;!hatmann paper discs. The discs wvere
allowed to dry overnight and treated wvith
10% cold TCA for 15 min followed by treat-
ment of 30 cold PCA for 15 min. The discs
AAere then rinsed twsTice M-ith methanol and
dried bv a quick wash of ether. The discs w-ere
further dried overnight and then transferred
to scintillation vials containing scintillation
fluid. The L3HI-TdR incorporated into DNA
wN-as measured on Beckmann Scintillation
Counter LS 100. Blastogenic Index (BI) wvas
calculated as follows:
BI
Absolute ct/min in antigen-treated
culture
Absolute ct/min in control culture
Tests showring BI of2 or more wNere considered
as posi'tive.
RESULTS
Table I gives the results of lymphocyte
transformation and leucocyte migration
inhibition assays carried out in 16 lympho-
cyte/leucocyte samples from CML patients
in remission. The antigens tested were
obtained from letukaemic cell samples from
6 CML patients, 1 CML patient with
blastic crisis, I AML patient, and 2 ALL
patients. Lymphocytes/leucocytes from
each remission patient were tested with
1-3 CML cell antigens. Most of the tests
were allogeneic, though in 4 cases autoch-
thonous antigens could be tested. It can
be seen that 12/39 LT tests carried out on
lymphocytes of CML patients in remis-
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TABLE I.- Reactions of C(lML patients in remission
Solubilized antigens obtained from
CAIL cells (from 1 of 6 patients)
*Test 1 Test 2
LT LMII LT LAII
2-20 0 30 2-30 0 34
1-96 0 59 2-05 044
2-14 0-21 1-98 0-39
1-84 0778 1-94 037
1-94 0-13
t2 40 0-32 199 0-67
1-23 1-07
2-10 0-27 1-81 0-79
1-66 0 47 1-73 0-84
1-87 0-68 1-71 0-91
2-13 0-28 1-88 0-78
1-29 0-98 1-66 047
1-89 0-67 t2-31 0-12
1-88 0-61
2-03 0 63 1-69 0-58
1-68 0 79
_(AL
Test 3 blasts
LT LAII L,T L1IT
1-99 0 57 1-79 090
2-11 0-71 1 99 0-63
187 074 1-83 069
1-06
1 58
1-86 073 2-42 0-23
1 69 0-61 1-38 0-41
2-21 0 43 1-51 0-25
tl-89 0-71 1-18
1-96 0-78 2-14 0 33
t2-33 0 19 2-45 0-62
113 0-87 2-02 1-44
2-34 0 59
1-03 0-76
1-95 0-66
1-96 0-58 1-71 0 44
AMIL
blasts
LT LAII
1 72 0-75
2-24 0-43
1-93 074
1-55
1-94
2-31 0-29
1-38 0-34
4-63 0-34
0-93
1-06
3-39 0-32
1-71 0-80
3-83 0-39
3-34 0-54
1-64 0-35
2-02 0-48
ALL blasts
C--
Test 1 Test 2
LT LAII LT LAIl
1-91 0-47 1-96 0-63
2-62 0-24 1-68 0-79
1-79 0-69 2-14 0-46
1-72 0-62
3-64
1-52
3-80
1-47
1-78
0-79
0-26
0-21
0-79
0-85
2-35 0-28
2-11 0-61
1-34 0 90
1-57 0-33
Total and i -
positive LT: 12/39 (31%) 5/16 (310o) 7/16 (440o) 6/16 (38
,actions LAMI: 34/39 (87%) 12/13 (92oo) 11/12 (920%) 14/16 (88
LT: Lymplhocyte transformation. Blastogenic Intlex > 2 is considered positive.
LMI: Leucocyte Migration Inhibition. Aligration Index <(080 or > 2 is considered positive.
Bold print denotes positiv e reactionls.
* Each test number carriedl ouit witlh aniy one of the 6 antigens.
t AutoclhtlhoInous ieactions.
i%)
So%)
sion, to different CML antigens, showed
positive blastogenesis (31%o) whilst 34/39
LMI tests showed inhibition of migration
(87%). From the autochthonous combina-
tions, patients AH 718, AH 14090 and
AJ 3172 have reacted well to autoch-
thonous antigens both by LT and LMI,
whilst patient Al 13118 has not reacted
to his own leukaemia-associated antigen
by LT and only weakly by LMI.
It is interesting to note that a significant
number of patients have reacted to blast
antigens. The reactivity with CML blast
antigen was 31%, whilst the reactivity
with AML blast antigens was 4400 with
LT and more than 9000 with LMI. CML
patients in remission have also reacted
with ALL blast antigens, the reactivity
being 38% with LT and 88% with LMI.
Table II shows the reactivities of a group
of 12 CML patients in remission to normal
PHA-activated lymphoblast antigen. It
was noted that 1/12 patients reacted to
this antigen preparation by LT, whilst
8/12 patients reacted with the normal
blasts antigen by LMI assay. Four ofthese
patients (AH 718, AH 14090, AH 16147
and AJ 9669) were tested with leukaemic-
blast antigens also (Table I). All of them
showed reactivity with CML-blast anti-
gens, 2 reacted to AML-blast antigens and
1 reacted to both ALL blast antigens.
None of these, however, showed positive
reactivity with normal PHA-transformed
lymphoblast antigen when tested with
both assays.
Table III shows the reactivities of a
group of 9 healthy individuals to
leukaemia-associated antigens. Each lym-
phocyte sample was tested with antigens
extracted from CML cells of 4 patients,
and blasts of 1 CML patient in blastic
crisis, 1 AML patient and 1 ALL patient.
The same antigens were tested on CML
patients in remission (Table I). It can be
seen that with CML antigens none of the
36 LT tests was positive, while 8/36 tests
were positive with LMI. Three healthy
controls reacted to CML-blast antigen by
LMI alone whilst none responded to AML
Lympho-
cyte/ I
leuco-
cyte
donors
AC 13403
AC 169
AC 3438
AD 5122
AF 5884
AH 718
AH 5866
AH 6739
AH 13118
AH 13347
AH 14090
AH 16147
AJ 3172
AJ 4744
AJ 9669
AJ 10407
re
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TABLE I. Reactions of CML patients in
remission to PHA-transformed lyimpho-
blast antigen
Patient LT' LEMI
AH 718 1-05 0-33
AHl 16147 0(98 0-48
AJ 9669 1.73 0-51
AJ 7251 0 96 0-53
AJ6123 2-59 0 47
AK 11051 1 55 (088
AK3179 1 27 09:3
AK 14634 11(0 0-78
AK 569:3 1 31 08:3
AK 13395 1 29 0-71
AK 14090 1-79 0-81
AL 1021 0( 78 0-68
No. teste(l } 1/12 8 12
blast antigens and one responded to ALL
blasts in the LMI test.
It can be seen from all 3 tables, that
LMI tests generally detected more positive
reactions. All the individuals showing
positive reactivity with the LT assay
showed LMI reaction with the same anti-
gen. It is felt that because of several
variables bevond control in the available
experimental procedures, cellularsensitiza-
tion of patients could be assessed better
by using more than one in vitr-o assay
(Haberman, 197:3). We lhave therefore
considered those patients who have showed
positive reactivity with both LT and LMI
assays as perhaps truly sensitized.
Table IN' gives a summary of the com-
parative reactivity pattern of the same
TABLE IV.-
reiftission
assays
-Data on CML patients in
reactive in both LT and LMI
Soluible anitigenIs from
PHA-
trans-
formed
C(NIL (CMf, AMIL, ALL lhmpho-
cells blasts blasts blasts blasts
No. positive*
reactions
,0 positix e
reactions
No. patients
reactive
00 patients
reactiVe
12/39 5/16- 7/16 6/16 1112
:31 31 44 38 8
8/16 5/16 7/16 5/11 1112
50 3 l 44 45 8
group of CML patients in remission, show-
ing positive reactivity with (lifferent
antigens by both assays. Since none ofthe
healthv controls reacted to leukaemia-
associated antigens by both the assays,
thev a,re not included in the Table. It, can
be seen that 31%0 of reactions with CML
antigens were positive with both tests,
while 8/16 (50°0) patients reacted to at,
least one CML antigen by botlh tests.
Whereas310%patients reacted toCMTLblast
antigens, 44oo reacted to AML blast
antigens and 45%0 reacted to ALL blast
antigens. C(onmpared to these reactions
with leukaemia-associated antigens, only
1/12 (8%) patients reacted to PHA-
transfornmed normal lymplhoblasts by both
assays.
TABLE III. Reactions of healthy individuals to leukaemia-associated antigensl
Solubilized anitigens obtainiect fIroim
Lymp}ho-
cyte/
leuco-
cyte
(lonors
MIA
NIr)
GH
KR
NS
I
C---
LT LAll
1l11 1 02
1]37 096
1-41 064
10-( 0*97
1*29 0*87
1-47 0-75
110 095
1-69 0(90
1-40 1 01
Total an( '
00 positive LT:
reactions [JAl r
(CXIL cells fr-om 4 p)atienits
LT f,A1I LT LMIl
1-33 1-03 1 09 1-01
1-32 0 91 1 13 1-08
1-49 0-81 107 056
1-45 1 06 1*11 1 02
1-20 0(83 0(94 1-01
1-39 0 49 1 23 0-82
1-33 1-05 0(93 1-38
1-493 0 73 1-65 1-06
1-54 0 82 1-47 062
0/:36 (Ooo)
8/36 (200o1')
4
r-
,LT LAIl
1 26 0 99
1-37 0'98
1 24 0(81
1-14 1 ()8
1-49 1-03
1 35 1-25
1-66 0891
1-29 0-81
CIAI1,
blasts
LT LMII
1*19 1 07
0 82 0 85
1 41 1*12
1-26 0-94
1 23 0(89
1-33 0 78
1-31 0-77
0-89 0.97
1 06 0 79
AMIL
blasts
LT LMI
1-24 09:3
0 88 1 03
1-43 0-93
1(10 1-02
1 41 0)93
1-18 0-85
1-47 0(91
1-17 0(95
1-40) 088
ALl
blasts
LT LM1
1-13 0 96
1-02 0(98
1*41 1*01
1-17 1-0(
1 11' 0-92
1-55 ().91
0.997 0-83
1-30 1-03
1J24 079
0/9 (0%) 0/9 ((o/Oo) 0/9 ((O/)
3/9 (330 ) (0/9 ()OO) 1/'3 (11I 0 )
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DISCUSSION
Our previous studies showed that CML
patients in remission were sensitized to
leukaemia-associated antigens (Gangal et
al., 1976, 1977). Since most, of the CML
patients eventually enter into blastic
crisis, and at that stage present, a clinical
picture simnilar to AML, it was thought
essential to study the reactivity of CML
patients to CML and AML blast antigens.
ALL antigens were also included in the
studies as lymphoid and myeloid blasts
are often morphologically indistinguish-
able and it has been suggested before that
anitisera to leukaemic cells cross-reacted
with myeloid and lvmphoid blasts (XWhit-
son et al., 1976; Staveni et al., 1977). In the
present series of experiments we have
attempte(d to investigate the cellular
reaction of CML patients in remission to
myeloid and lymphoid blast, antigens.
Out ofthe 1 6 CML patients investigated,
3 reacted to CML and CML blast antigens,
3 reacted to CML and AML blast antigens,
5 reacted to ALL blast antigens, whilst
2 reacted to CML antigens as well as
CML, AML and ALL blast antigens.
Patient AC' 16(59, who showed borderline
p)ositive reaction with CML blast antigens
and positive reaction to all other antigens
tested, has nowv entered into blastic crisis.
It would be interesting to follow the
course of disease in the 2 patients (AH
14090 and AJ 3172), who reacted to all
antigens. One out of 12 CML patients in
remnission also reactedtoPBA-transformed
normal lymphoblasts. A group of 9 healthy
controls, tested with the same panel of
leukaemia-associated antigens, however,
did not show positive reactions with both
assays.
Recently a great (leal of serological
evidence has been put, forwNard indicating
cross reactivities between myelogenous
leukaemias, ALL and B-cell malignancies
as well as lymphoblastoid B-cell lines
(WN;hitson et al., 1976; Zighelboim et al.,
1977; Billing et al., 1977; Staven et al.,
1977; Drew et al., 1977; Mohankumar
et al., 1978; Roberts & Greaves, 1978).
Non-human primate sera to leukaemic
cells as well as to normal lymphocytes,
serum obtained from a multiparous CML
patient with multiple transfusions, and
rabbit antisera to a Ph'-positive leukemic-
cell line have been used to show shared
antrigens between myeloid and lymphoid
malignancies. Our studies have revealed
cellular sensitization of CML patients in
remission to antigens obtained from
myeloid and lymphoid leukaemic blasts.
In addition, 1/12 CML patients in remis-
sioni reacted to PHA-activated normal
lymphoblast antigens by LT assay, while
8/12 reacted in LMI test. Zighelboim et al.
(1977) have not been able to detect sero-
logical reactivity with PHA-activated
lymphoblasts. Sondal et al. (1976) also
failed to demonstrate cytotoxicity of in
vitro sensitized lymphocytes of HL-A-
matched siblings of leukaemic patients
to PHA transformed lymphocytes.
The reactivities revealed in the present
stu(lies thus suggest the presence of cross-
reacting antigens shared by immature
myeloid cells, myeloid and lymphoid
leukaemic blasts and, to some extent,
normal lymphoblasts. It is possible that
these reactivities may be reflecting sen-
sitization of CML patients to antigens of
immature cells shared with cells ofmyeloid
and lymphoid lineages rather than the
true letukaemia-specific sensitization.
This wvork 'was Su1pported by the Lady Tata
AMemnorial Trust Research Grant for Leukaemia
Research foI whiceh the autlhors aie grateful.
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